Literature DB >> 21690446

Hilar cholangiocarcinoma: tumor depth as a predictor of outcome.

Mechteld C de Jong1, Seung-Mo Hong, Mathew M Augustine, Michael G Goggins, Christopher L Wolfgang, Kenzo Hirose, Richard D Schulick, Michael A Choti, Robert A Anders, Timothy M Pawlik.   

Abstract

BACKGROUND: The American Joint Committee on Cancer staging system for hilar cholangiocarcinoma may be inaccurate because the bile duct lacks discrete tissue boundaries.
OBJECTIVES: To examine the accuracy of the American Joint Committee on Cancer staging schemes and to determine the prognostic implications of tumor depth. DESIGN, SETTING, AND PATIENTS: From January 1, 1987, through December 31, 2009, there were 106 patients who underwent resection of hilar cholangiocarcinoma who had pathologic slides available for re-review. MAIN OUTCOME MEASURES: Tumor depth and overall survival.
RESULTS: Overall median survival was 19.9 months. The 6th and 7th editions of the T-classification criteria were unable to discriminate among T1, T2, and T3 lesions (P > .05 for all). Median survival was associated with the invasion depth of the tumor (≥5 mm vs <5 mm): 18 months vs 30 months (P = .01). On multivariate analysis, tumor depth remained predictive of disease-specific death (hazard ratio, 1.70; P = .03).
CONCLUSIONS: The American Joint Committee on Cancer T-classification criteria did not stratify patients with regard to prognosis. Depth of tumor invasion is a better predictor of long-term outcome.

Entities:  

Mesh:

Year:  2011        PMID: 21690446      PMCID: PMC3308171          DOI: 10.1001/archsurg.2011.122

Source DB:  PubMed          Journal:  Arch Surg        ISSN: 0004-0010


  30 in total

1.  Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma.

Authors:  W R Jarnagin; Y Fong; R P DeMatteo; M Gonen; E C Burke; J Bodniewicz BS; M Youssef BA; D Klimstra; L H Blumgart
Journal:  Ann Surg       Date:  2001-10       Impact factor: 12.969

2.  Smooth muscle distribution in the extrahepatic bile duct: histologic and immunohistochemical studies of 122 cases.

Authors:  S M Hong; G H Kang; H Y Lee; J Y Ro
Journal:  Am J Surg Pathol       Date:  2000-05       Impact factor: 6.394

Review 3.  Improved surgical results for hilar cholangiocarcinoma with procedures including major hepatic resection.

Authors:  T Kosuge; J Yamamoto; K Shimada; S Yamasaki; M Makuuchi
Journal:  Ann Surg       Date:  1999-11       Impact factor: 12.969

Review 4.  Hilar cholangiocarcinoma: a review and commentary.

Authors:  R S Chamberlain; L H Blumgart
Journal:  Ann Surg Oncol       Date:  2000 Jan-Feb       Impact factor: 5.344

Review 5.  Cholangiocarcinoma of the extrahepatic bile ducts.

Authors:  W R Jarnagin
Journal:  Semin Surg Oncol       Date:  2000 Sep-Oct

6.  Long-term outcome of extended hemihepatectomy for hilar bile duct cancer with no mortality and high survival rate.

Authors:  Yasuji Seyama; Keiichi Kubota; Keiji Sano; Tamaki Noie; Tadatoshi Takayama; Tomoo Kosuge; Masatoshi Makuuchi
Journal:  Ann Surg       Date:  2003-07       Impact factor: 12.969

7.  Major hepatectomy for perihilar cholangiocarcinoma.

Authors:  Michiaki Unno; Yu Katayose; Toshiki Rikiyama; Hiroshi Yoshida; Kuniharu Yamamoto; Takanori Morikawa; Hiroki Hayashi; Fuyuhiko Motoi; Shinichi Egawa
Journal:  J Hepatobiliary Pancreat Sci       Date:  2009-11-26       Impact factor: 7.027

Review 8.  The epidemiology of cholangiocarcinoma.

Authors:  Yasser Shaib; Hashem B El-Serag
Journal:  Semin Liver Dis       Date:  2004-05       Impact factor: 6.115

Review 9.  Surgical management of cholangiocarcinoma.

Authors:  William R Jarnagin; Margo Shoup
Journal:  Semin Liver Dis       Date:  2004-05       Impact factor: 6.115

10.  Intrahepatic cholangioenteric anastomosis in carcinoma of the hilus of the liver.

Authors:  H Bismuth; M B Corlette
Journal:  Surg Gynecol Obstet       Date:  1975-02
View more
  19 in total

1.  Improved surgical outcomes for hilar cholangiocarcinoma: changes in surgical procedures and related outcomes based on 40 years of experience at a single institution.

Authors:  Ryota Higuchi; Takehiro Ota; Takehisa Yazawa; Hideki Kajiyama; Tatsuo Araida; Toru Furukawa; Tatsuya Yoshikawa; Ken Takasaki; Masakazu Yamamoto
Journal:  Surg Today       Date:  2015-02-05       Impact factor: 2.549

2.  The pathologic correlation between liver and portal vein invasion in perihilar cholangiocarcinoma: evaluating the oncologic rationale for the American Joint Committee on Cancer definitions of T2 and T3 tumors.

Authors:  Takaaki Ito; Tomoki Ebata; Yukihiro Yokoyama; Tsuyoshi Igami; Gen Sugawara; Takashi Mizuno; Yoshie Shimoyama; Masato Nagino
Journal:  World J Surg       Date:  2014-12       Impact factor: 3.352

Review 3.  Perihilar cholangiocarcinoma: Current therapy.

Authors:  Wei Zhang; Lu-Nan Yan
Journal:  World J Gastrointest Pathophysiol       Date:  2014-08-15

Review 4.  Curative-intent surgery for hilar cholangiocarcinoma: prognostic factors for clinical decision making.

Authors:  Irinel Popescu; Traian Dumitrascu
Journal:  Langenbecks Arch Surg       Date:  2014-05-20       Impact factor: 3.445

Review 5.  Multimodality Management of Localized Biliary Cancer.

Authors:  Nadia Ashai; Preethi Prasad; Lakshmi Rajdev
Journal:  Curr Treat Options Oncol       Date:  2019-05-29

Review 6.  Perioperative Management of Hilar Cholangiocarcinoma.

Authors:  Katherine E Poruk; Timothy M Pawlik; Matthew J Weiss
Journal:  J Gastrointest Surg       Date:  2015-05-29       Impact factor: 3.452

7.  Impact of tumor localization on the outcomes of surgery for an intrahepatic cholangiocarcinoma.

Authors:  Tatsuya Orimo; Toshiya Kamiyama; Tomoko Mitsuhashi; Hirofumi Kamachi; Hideki Yokoo; Kenji Wakayama; Shingo Shimada; Akihisa Nagatsu; Akinobu Taketomi
Journal:  J Gastroenterol       Date:  2018-05-02       Impact factor: 7.527

8.  Surgical strategies in patients with advanced hilar cholangiocarcinoma (Klatskin tumor).

Authors:  J R Izbicki; T Y Tsui; B A Bohn; M Bockhorn
Journal:  J Gastrointest Surg       Date:  2012-12-14       Impact factor: 3.452

Review 9.  Multimodal treatment strategies for advanced hilar cholangiocarcinoma.

Authors:  Matthew J Weiss; David Cosgrove; Joseph M Herman; Neda Rastegar; Ihab Kamel; Timothy M Pawlik
Journal:  Langenbecks Arch Surg       Date:  2014-06-25       Impact factor: 3.445

Review 10.  Management of perihilar cholangiocarcinoma in the era of multimodal therapy.

Authors:  Vicente Valero; David Cosgrove; Joseph M Herman; Timothy M Pawlik
Journal:  Expert Rev Gastroenterol Hepatol       Date:  2012-08       Impact factor: 3.869

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.